ACRS Stock Analysis: Buy, Sell, or Hold?
ACRS - Aclaris Therapeutics, Inc.
$3.49
-0.04 (-0.99%)
▼
5d:
-2.65%
30d:
+21.43%
90d:
+15.02%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
ACRS is down 4.6% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 1,429 OI. Call ratio: 100% View Scanner →
Strength: 7.3/10
Get Alerted When ACRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACRS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ACRS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ACRS is currently trading at $3.48, which is considered slightly high relative to its 30-day fair value range of $3.13 to $3.64.
Technical Outlook: Technically, ACRS is in a uptrend. Immediate support is located at $3.20, while resistance sits at $3.94.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.29 (+135.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACRS is in a uptrend. Immediate support is located at $3.20, while resistance sits at $3.94.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.29 (+135.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$3.13 -
$3.64
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 135.4% below Wall St target ($8.29)
Fair Price Analysis
30-Day Fair Range
$3.13 -
$3.64
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.20
Resistance Level
$3.94
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.69
Wall Street Target
$8.29
(+135.4%)
Revenue Growth (YoY)
-85.9%
Share & Embed Analysis
Last updated: March 30, 2026 11:55 AM ET
Data refreshes hourly during market hours. Next update: 12:55 PM
Data refreshes hourly during market hours. Next update: 12:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
